Eli Lilly to Acquire AtaiBeckley for up to $3.8 Billion
July 17, 2026
In a bold expansion of its neuroscience portfolio, Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc.,...
Read more
Merck’s Lipfendra (Enlicitide) Receives Historic FDA Approval as the First Oral PCSK9 Inhibitor
July 16, 2026
Merck Lipfendra approval, enlicitide FDA, oral PCSK9 inhibitor, hypercholesterolemia treatment, new cholesterol drug 2026. In a landmark development for cardiovascular...
Read more